Target Information
Target General Infomation | |||||
---|---|---|---|---|---|
Target ID |
T16156
|
||||
Former ID |
TTDS00524
|
||||
Target Name |
Thrombopoietin Receptor
|
||||
Gene Name |
MPL
|
||||
Synonyms |
C-mpl; CD110 antigen; Myeloproliferative leukemia protein; TPO-R; TPOR; MPL
|
||||
Target Type |
Successful
|
||||
Disease | Acute myeloid leukemia [ICD9: 205; ICD10: C92.0] | ||||
Bone marrow transplantation [ICD9: 279.5, 996; ICD10: D89.8, T86] | |||||
Chronic liver disease; HCV induced thrombocytopaenia [ICD9: 287.3, 287.4, 287.5; ICD10: D69.6, P61.0] | |||||
Chemotherapy-induced thrombocytopenia; Myelodysplastic syndromes [ICD9: 238.7, 287.3, 287.4, 287.5; ICD10: D46, D69.6, P61.0] | |||||
Idiopathic thrombocytopenic purpura [ICD9: 287.31; ICD10: D69.3] | |||||
Immune thrombocytopenic purpura; Idiopathic thrombocytopenic purpura [ICD9: 287.31; ICD10: D69.3] | |||||
Liver disease [ICD9: 570-574; ICD10: K70-K77] | |||||
Myocardial infarction; Thrombotic stroke [ICD9:410, 434.91; ICD10: I21, I22, I61-I63] | |||||
Oncology-related thrombocytopaenia [ICD9: 287.3, 287.4, 287.5; ICD10: D69.6, P61.0] | |||||
Sarcoma; Idiopathic thrombocytopenic purpura [ICD9: 287.31; ICD10: D69.3] | |||||
Thrombocytopenic purpura [ICD10: D69] | |||||
Thrombocytopenia [ICD9: 287.3, 287.4, 287.5; ICD10: D69.6, P61.0] | |||||
Unspecified [ICD code not available] | |||||
Function |
Receptor for thrombopoietin. May represent a regulatory molecule specific for TPO-R-dependent immune responses.
|
||||
BioChemical Class |
Type I cytokine receptor
|
||||
Target Validation |
T16156
|
||||
UniProt ID | |||||
Sequence |
MPSWALFMVTSCLLLAPQNLAQVSSQDVSLLASDSEPLKCFSRTFEDLTCFWDEEEAAPS
GTYQLLYAYPREKPRACPLSSQSMPHFGTRYVCQFPDQEEVRLFFPLHLWVKNVFLNQTR TQRVLFVDSVGLPAPPSIIKAMGGSQPGELQISWEEPAPEISDFLRYELRYGPRDPKNST GPTVIQLIATETCCPALQRPHSASALDQSPCAQPTMPWQDGPKQTSPSREASALTAEGGS CLISGLQPGNSYWLQLRSEPDGISLGGSWGSWSLPVTVDLPGDAVALGLQCFTLDLKNVT CQWQQQDHASSQGFFYHSRARCCPRDRYPIWENCEEEEKTNPGLQTPQFSRCHFKSRNDS IIHILVEVTTAPGTVHSYLGSPFWIHQAVRLPTPNLHWREISSGHLELEWQHPSSWAAQE TCYQLRYTGEGHQDWKVLEPPLGARGGTLELRPRSRYRLQLRARLNGPTYQGPWSSWSDP TRVETATETAWISLVTALHLVLGLSAVLGLLLLRWQFPAHYRRLRHALWPSLPDLHRVLG QYLRDTAALSPPKATVSDTCEEVEPSLLEILPKSSERTPLPLCSSQAQMDYRRLQPSCLG TMPLSVCPPMAESGSCCTTHIANHSYLPLSYWQQP |
||||
Drugs and Mode of Action | |||||
Drug(s) | Eltrombopag | Drug Info | Approved | Thrombocytopenia | [529941], [541996] |
PROMACTA | Drug Info | Approved | Thrombocytopenia | [543468] | |
Revolade/Promacta | Drug Info | Approved | Idiopathic thrombocytopenic purpura | [538590] | |
Romiplostim | Drug Info | Approved | Thrombocytopenia | [529941], [542005] | |
E5501 | Drug Info | Phase 3 | Idiopathic thrombocytopenic purpura | [523622] | |
Eltrombopag | Drug Info | Phase 3 | Idiopathic thrombocytopenic purpura | [536737], [541996] | |
Revolade/Promacta | Drug Info | Phase 3 | Chronic liver disease; HCV induced thrombocytopaenia | [538590] | |
LGD-4665 | Drug Info | Phase 2 | Immune thrombocytopenic purpura; Idiopathic thrombocytopenic purpura | [536737] | |
Revolade/Promacta | Drug Info | Phase 2 | Oncology-related thrombocytopaenia | [538590] | |
Romiplostim | Drug Info | Phase 2 | Chemotherapy-induced thrombocytopenia; Myelodysplastic syndromes | [536737], [542005] | |
S-888711 | Drug Info | Phase 2 | Liver disease | [522925] | |
BVI-007 | Drug Info | Phase 1 | Myocardial infarction; Thrombotic stroke | [548615] | |
NIP-004 | Drug Info | Phase 1 | Thrombocytopenia | [548679] | |
RhTPO | Drug Info | Discontinued in Phase 3 | Sarcoma; Idiopathic thrombocytopenic purpura | [536737] | |
Thrombopoietin | Drug Info | Discontinued in Phase 3 | Thrombocytopenia | [468146], [547808] | |
Totrombopag | Drug Info | Discontinued in Phase 1 | Thrombocytopenia | [536737] | |
Promegapoietin | Drug Info | Terminated | Bone marrow transplantation | [546819] | |
Agonist | AS-1670542 | Drug Info | [543468] | ||
E5501 | Drug Info | [543468] | |||
Eltrombopag | Drug Info | [536737] | |||
LGD-4665 | Drug Info | [536737] | |||
NIP-004 | Drug Info | [528043] | |||
PROMACTA | Drug Info | [543468] | |||
Revolade/Promacta | Drug Info | [550963] | |||
RhTPO | Drug Info | [536737] | |||
S-888711 | Drug Info | [544267] | |||
SB-559457 | Drug Info | [543468] | |||
STS-T4 | Drug Info | [543468] | |||
Thrombopoietin | Drug Info | [535128] | |||
Totrombopag | Drug Info | [550963] | |||
Antagonist | BVI-007 | Drug Info | [543468] | ||
HL-034 | Drug Info | [543468] | |||
Modulator | Non-peptide TPO mimics | Drug Info | [543468] | ||
Promegapoietin | Drug Info | [556264] | |||
RI-TPO | Drug Info | [1572605] | |||
Romiplostim | Drug Info | [529941] | |||
SE-ET-TP020d | Drug Info | [1572605] | |||
ThromboMer | Drug Info | [543468] | |||
thrombopoietin antagonist | Drug Info | [1572605] | |||
thrombopoietin mimetic antibodies | Drug Info | [1572605] | |||
TPO therapy program, thrombocytopenia | Drug Info | [543468] | |||
Target Expression Profile (TEP) and Drug Resistance Mutation (DRM) | |||||
TEP | EXP Info | ||||
Pathways | |||||
KEGG Pathway | Cytokine-cytokine receptor interaction | ||||
Jak-STAT signaling pathway | |||||
WikiPathways | Platelet Aggregation (Plug Formation) | ||||
References | |||||
Ref 468146 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5063). | ||||
Ref 522925 | ClinicalTrials.gov (NCT01054443) A Study to Investigate the Efficacy and Safety of S-888711 Tablets Administered to Adult Subjects With Immune Thrombocytopenia (ITP). U.S. National Institutes of Health. | ||||
Ref 523622 | ClinicalTrials.gov (NCT01433978) A Phase 3, Multicenter, Randomized, Double-blind, Active-controlled, Parallel-group Trial With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Oral E5501 Versus Eltrombopag, in Adults With Chronic Immune Thrombocytopenia (Idiopathic Thrombocytopenic Purpura). U.S. National Institutes of Health. | ||||
Ref 536737 | Emerging drugs for idiopathic thrombocytopenic purpura in adults. Expert Opin Emerg Drugs. 2008 Jun;13(2):237-54. | ||||
Ref 538590 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 022291. | ||||
Ref 541996 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6961). | ||||
Ref 542005 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6974). | ||||
Ref 543468 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1722). | ||||
Ref 546819 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010450) | ||||
Ref 547808 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019480) | ||||
Ref 528043 | A novel nonpeptidyl human c-Mpl activator stimulates human megakaryopoiesis and thrombopoiesis. Blood. 2006 Jun 1;107(11):4300-7. Epub 2006 Feb 16. | ||||
Ref 535128 | Technology evaluation: thrombopoietin, Genentech/Pharmacia & Upjohn. Curr Opin Mol Ther. 2000 Apr;2(2):211-5. | ||||
Ref 536737 | Emerging drugs for idiopathic thrombocytopenic purpura in adults. Expert Opin Emerg Drugs. 2008 Jun;13(2):237-54. | ||||
Ref 543468 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1722). |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.